Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Seagen, a wholly owned subsidiary of Pfizer
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04579380CT.gov Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Tumor Of Uterus
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab (this asset) | Seagen, a wholly owned subsidiary of Pfizer | P2 | CCC · 53 |
| Fulvestrant | Atavistik Bio, Inc | P2 | B |
| Nogitecan | Montefiore Medical Center | P2 | B |
| Adriamycin | AGO Study Group | P2 | B |
| Carboplatin | AGO Study Group | P2 | B |
| Docetaxel | Montefiore Medical Center | P2 | B |
| Tucatinib | Seagen, a wholly owned subsidiary of Pfizer | P2 | CCC |
| Atv-1601 | Atavistik Bio, Inc | P1 | CC |
Other indications for Trastuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 76 |
| Inflammatory Breast Carcinoma | — | P3 | BBB · 74 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trastuzumab in Tumor Of Uterus. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trastuzumab-tumor-of-uterus
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →